For swine and poultry operations administering oral antimicrobials or antiparasitic agents via drinking water, Zhuyun Powder Veterinary Grade API is formulated as a water-soluble or water-dispersible powder in which the active ingredient is blended with dextrose monohydrate, sodium chloride, anhydrous citric acid, and a low-foaming wetting agent. Compliance is anchored to Ph. Eur. 5.1.4 for microbiological quality of non-sterile oral powders, VICH GL18 for residual solvent control in veterinary drug substances, and EudraLex Volume 4 Part 1 Chapter 5 for production and in-process control; batch release includes loss on drying per Ph. Eur. 2.2.32 and content uniformity per Ph. Eur. 2.9.40, with an acceptance value of ≤15.0 for single-dose units. Formulation addition ratios place the API at 5% w/w to 50% w/w, carrier excipients at 45% w/w to 90% w/w, and buffering acids at 0.5% w/w to 2.0% w/w; the exact loaded amount is back-calculated from the labelled dose per litre of drinking water so that reconstitution of 100 g in 100 L to 200 L delivers a measurable dose volume per kg body weight. If the API assay is 95.0% to 102.0% on dried basis, a factor of assay/100 is applied during weighing to correct for potency. The downstream production process begins with geometric dilution of the API in a double-cone or V-blender at 60% to 80% nominal fill volume and 15 rpm to 25 rpm; the premix is passed through a 0.500 mm in-line sieve before final blending. Blending time is fixed by sampling at 5 min, 10 min, and 15 min and assaying content uniformity because prolonged blending can induce electrostatic segregation of fine API from coarse dextrose particles. Filling into moisture-proof LDPE-aluminium foil sachets is performed under controlled humidity below 40% RH, and each batch is checked for fill weight variation using an automatic checkweigher set to reject units outside ±1% of target. Terminal finished product types include 100 g, 250 g, 500 g, and 1 kg water-soluble powder sachets; 100 g polypropylene jars; and bulk polyethylene liners for direct farm dispensing. Published data for this specific API configuration is limited, and the addition ratio should be verified by pilot blending rather than transferred directly from unrelated compounds.

Table 1. Compliance matrix applied across downstream veterinary dosage forms.

When a Veterinary Injection Is Terminally Sterilised Instead of Aseptically Filtered

Depending on whether the final injection is terminally sterilised or aseptically filtered, the formulation composition and process validation package change materially for sterile veterinary injections containing the API as a solution or suspension. Compliance is maintained against Ph. Eur. 5.1.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, Ph. Eur. 2.9.19 for sub-visible particulate contamination, FDA 21 CFR 211.110 for in-process sampling, and USP <1207> for container closure integrity evaluation; if the product is filled as a terminally sterilised solution, a sterilising cycle of 121°C for 15 min in an autoclave with a load probe in the coldest vessel is typically used. The formulation addition ratio places the API at 0.5% w/v to 20% w/v, water for injection at 60% v/v to 95% v/v, co-solvents such as propylene glycol at 10% v/v to 40% v/v where aqueous solubility is insufficient, and benzyl alcohol at 1% v/v to 2% v/v as a preservative in multi-dose vials. The downstream process requires a 316L stainless steel jacketed vessel with nitrogen overlay to prevent oxidation, and the API is pre-milled to d90 < 15 µm if the final product is a suspension rather than a true solution. Dissolution is followed by pH adjustment to 4.0 to 7.0, clarification through a 0.45 µm prefilter, and sterilising filtration through a 0.22 µm PVDF membrane under positive nitrogen pressure. If the API degrades in aqueous solution under terminal steam heat, the batch is aseptically filtered and filled in an ISO Class 5 cleanroom; otherwise the solution is autoclaved and the steam sterilisation cycle is validated by biological indicators. A process-scale failure mode observed on injectable lines is filter blocking when the API is milled to d90 above 15 µm or dissolved at temperatures below 20°C; a 0.45 µm prefilter removes gross aggregates but does not correct a poor dissolution profile. Terminal finished product types include 50 mL, 100 mL, and 250 mL Type II glass vials, 500 mL multi-dose bottles, and pre-filled syringes where the closure system is validated by dye ingress. Buffered systems containing phosphate should be avoided if the API forms insoluble phosphate salts at the target pH. Published data for this specific API configuration is limited; thermal stability data at 60°C for 7 days should be generated before selecting terminal sterilisation.

How Does Direct Compression Alter Content Uniformity for Low-Dose Veterinary Tablets?

Initially, direct compression is adopted only after a preformulation assessment demonstrates that the API exhibits bulk density above 0.40 g/mL, Carr index below 25, and a particle size distribution with d90 below 250 µm; otherwise the formulation is shifted to wet granulation. The tablet compliance package references Ph. Eur. 2.9.40 for content uniformity, Ph. Eur. 2.9.5 for mass uniformity, Ph. Eur. 2.9.7 for friability, and ICH Q3D for elemental impurity risk assessment. The formulation addition ratio places the API at 5% w/w to 60% w/w, microcrystalline cellulose at 15% w/w to 40% w/w, lactose monohydrate at 10% w/w to 30% w/w, crospovidone at 2% w/w to 5% w/w, and magnesium stearate at 0.5% w/w to 1.5% w/w. When the unit dose is below 5 mg, an ordered mixing step is introduced using a carrier fraction with a similar particle size to the API to reduce segregation. The downstream process uses a bin blender at 10 rpm to 20 rpm for 15 min to 25 min, followed by a rotary tablet press operating at 20 rpm to 80 rpm with compression force 8 kN to 25 kN; force feeder speed is adjusted to maintain die fill variation below 1.5%. On production-scale presses, capping and lamination occur when the compression force exceeds the plastic deformation threshold of the filler or when the lubricant contact time is above 15 min; magnesium stearate is therefore added in the final mixing stage. Tablet hardness is quantified on a Ph. Eur. 2.9.8 tester and is typically held at 30 N to 80 N, with friability not more than 1.0%. Terminal finished product types include 25 mg, 50 mg, 100 mg, and 250 mg scored tablets; chewable tablets for dogs and cats using liver digest or yeast-based flavour systems; and film-coated tablets when the API taste is objectionable. Direct compression should be avoided if the API has both low bulk density below 0.30 g/mL and electrostatic charge, because the blend stratifies under high-speed press vibration. Published data for this specific API configuration is limited; a 3-batch pilot study with content uniformity sampling at 10 min intervals is recommended.

In integrated feed mills, medicated premix lines require the API to be incorporated not as a finished dosage unit but as an intermediate blend with a defined carrier fraction, typically calcium carbonate, ground corn cob, wheat middlings, or rice hulls. The regulatory controls are Regulation (EC) No 183/2005 on feed hygiene, Regulation (EU) 2019/4 on medicated feed, ISO 6497:2002 for sampling of animal feeding stuffs, and HACCP verification according to Codex Alimentarius CXC 1-1969. The formulation addition ratio places the API at 0.5% w/w to 10% w/w in the premix, carrier at 80% w/w to 98% w/w, mineral oil or light liquid paraffin binder at 0.5% w/w to 2.0% w/w, and an anti-dust fraction below 5% w/w; the final feed inclusion rate is calculated so that the premix is diluted at 0.5 kg/t to 10 kg/t in complete feed. The manufacturing process uses sequential dilution in 1:10 steps, beginning with a small API-carrier pre-blend and expanding to the full batch in a ribbon blender or paddle mixer with tip speed 1.0 m/s to 2.5 m/s and mixing time 8 min to 15 min. Homogeneity is confirmed by sampling at multiple points per ISO 6497:2002 and assaying a marker or the API; the coefficient of variation should remain below 5%, and a documented flushing sequence is required to control carryover to the next non-medicated feed batch. Processing limitations include a maximum carrier moisture of 12% and avoidance of concentrated acidic or alkaline feed additives in the same premix unless compatibility data are available. Terminal finished product types include 5 kg, 10 kg, 20 kg, and 25 kg multi-wall paper or woven polypropylene sacks with inner polyethylene liners, and bulk tote bags for integrated feed mills. Published data for this specific API configuration is limited, and the exact dilution ratio should be derived from the registered veterinary medicine label rather than from generic premix recommendations.

Hard Capsule Filling Parameters for Equine and Companion-Animal Oral Formulations

Because hard capsule filling machines are less tolerant of poor powder rheology than tablet presses, encapsulation of the API into hard gelatin or HPMC shells begins with a low-shear blending step that must control both powder flow and content uniformity. The compliance package references Ph. Eur. 2.9.1 for disintegration, Ph. Eur. 2.9.5 for mass uniformity, USP <711> for dissolution where a dissolution test is required by the product profile, and EudraLex Volume 4 Part 1 for manufacturing controls. The formulation addition ratio places the API at 10% w/w to 70% w/w, lactose monohydrate at 20% w/w to 85% w/w, magnesium stearate at 0.5% w/w to 1.5% w/w, and colloidal silicon dioxide at 0.2% w/w to 0.5% w/w; the target fill weight is 250 mg to 500 mg for size 0 or 1 capsules. The downstream process uses a bin blender or double-cone blender at 10 rpm to 20 rpm, followed by a continuous capsule filling machine with dosator or tamping pin stations. Tamping pin pre-compression is set in the range 10 N to 15 N, and pellet density is adjusted to achieve a fill weight relative standard deviation below 2.0% across empty shell weight classes. Moisture in the filling suite is held below 45% RH because both gelatin and HPMC shell brittleness or softening can shift with humidity, and hygroscopic excipients such as sorbitol are avoided unless the process is validated at lower humidity. Process-scale failure modes include powder plug ejection after tamping stations when colloidal silicon dioxide is omitted, and stick-slip flow in the hopper when the blend contains agglomerates above 800 µm. Terminal finished product types include 250 mg, 500 mg, and 1 g hard gelatin capsules, HPMC capsules for vegetarian or halal-required markets, and bulk containers for veterinary clinics. If the API is oily or has a low melting point, liquid-filled capsule equipment is a separate process and requires a different risk assessment under Ph. Eur. 2.9.1. Published data for this specific API configuration is limited, and the powder plug ejection threshold should be established on the actual capsule machine before scale-up.

Fluid-Bed Granulation of Oral Powders at Moisture Thresholds Below 35% RH

For oral administration to calves, piglets, and poultry, top-spray fluid-bed granulation converts the API powder and a carrier system into free-flowing granules with a target moisture content below 2.0%, reducing dust generation and improving dissolution. The standards framework for granular veterinary powders includes Ph. Eur. 5.1.4 for microbiological quality, Ph. Eur. 2.9.40 for content uniformity, Ph. Eur. 2.9.31 for particle size distribution by laser diffraction, and ICH Q3D for elemental impurities. The formulation addition ratio places the API at 1% w/w to 30% w/w, carrier such as sucrose spheres or microcrystalline cellulose at 60% w/w to 95% w/w, binder such as hydroxypropyl methylcellulose at 1% w/w to 5% w/w, and talc or colloidal silicon dioxide at 0.5% w/w to 2.0% w/w to reduce tack. The downstream process is run in a top-spray fluid-bed granulator with inlet air temperature 50°C to 70°C, product temperature 30°C to 40°C, exhaust relative humidity below 35%, spray rate 5 g/min to 15 g/min per kg of bed mass, and atomising air pressure 1.0 bar to 2.5 bar. Drying is continued after binder spray-out until loss on drying per Ph. Eur. 2.2.32 is below 2.0%, then the granules are sieved through 1.0 mm and 0.150 mm screens to remove oversize and fines. A process limit occurs when product temperature exceeds 45°C or spray rate exceeds the bed evaporation capacity, causing overwetting, defluidisation, and uncontrolled agglomeration; the binder solution should be added in small increments with bed pressure drop monitored. Terminal finished product types include 20 g, 100 g, and 500 g granular sachets; 1 kg bulk jars; and granules for reconstitution into oral solution or for direct mixing into liquid feed. If the granules are intended for feed use rather than direct oral dosing, the final blend must also comply with Regulation (EU) 2019/4 where applicable. Published data for this specific API configuration is limited, and a feasibility batch should be run at low spray rate to avoid heat-labile API degradation.